By Najat Kantouar


GSK said it reached a confidential settlement with a plaintiff over its discontinued drug Zantac, resolving the case in an Illinois state court.

The British pharmaceutical company said Friday that it won't admit any liability in this settlement, and added that the scientific consensus didn't find any consistent or reliable evidence that ranitidine, commonly sold under the brand name Zantac, increases the risk of any cancer.

In 2020, the U.S. Food and Drug Administration requested manufacturers take Zantac off the market. The FDA concluded that the drug's ingredient, ranitidine, can form a cancer-causing contaminant, N-Nitrosodimethylamine, over time or through heat exposure.

GSK said that it would continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.


Write to Najat Kantouar at najat.kantouar@wsj.com


(END) Dow Jones Newswires

06-28-24 1327ET